

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.  
URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2024.04.01.~2024.04.07.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

## ○ 미국 58건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06351124</a>	Beta-Hydroxybutyrate Feasibility Treating IBS	Biological: Feasibility of beta-hydroxybutyrate supplementation to reduce inflammation in patients with Inflammatory Bowel Disease	University of Texas at Austin	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06351124</a>
<a href="#">NCT06320405</a>	Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors	Biological: Axatilimab Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Drug: Paclitaxel Procedure: Positron Emission Tomography Biological: Retifanlimab	OHSU Knight Cancer Institute Oregon Health and Science University Incyte Corporation	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06320405</a>
<a href="#">NCT06249191</a>	Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma	Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Bone Marrow Aspiration and Biopsy Procedure: Computed Tomography Drug: Cyclophosphamide Drug: Doxorubicin Procedure: Echocardiography Drug: Etoposide Procedure: Magnetic Resonance Imaging Biological: Mosunetuzumab Procedure: Multigated Acquisition Scan Procedure: Positron Emission Tomography Drug: Prednisone Drug: Vincristine	OHSU Knight Cancer Institute Genentech, Inc. Oregon Health and Science University	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06249191</a>
<a href="#">NCT06238921</a>	Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases	Radiation: Stereotactic Radiation Drug: Zimberelimab Drug: Sacituzumab govitecan	H. Lee Moffitt Cancer Center and Research Institute Gilead Sciences	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06238921</a>
<a href="#">NCT06113003</a>	The Gut, Liver And Metabolome in Human Immunodeficiency Virus and Non Alcoholic Fatty Liver Disease	Dietary Supplement: Prebiotic Dietary Supplement: Probiotic	Vanderbilt University Medical Center	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06113003</a>
<a href="#">NCT06106672</a>	Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis	Drug: CNP-106 Other: Placebo	COUR Pharmaceutical Development Company, Inc.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06106672</a>
<a href="#">NCT06053242</a>	Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Back Pain	Drug: CELZ-201-DDT Other: Placebo	Creative Medical Technology Holdings Inc	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06053242</a>
<a href="#">NCT05669352</a>	A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab Following Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases	Drug: CA-4948 Drug: Pembrolizumab	University of Florida Merck Sharp & Dohme LLC	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05669352</a>
<a href="#">NCT04085887</a>	Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures	Drug: Panitumumab-IRDye800 Device: Pinpoint-IR9000 endoscopic/handheld device Device: Explorer Air camera Device: PDE-NEO-II	Stanford University	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT04085887</a>
<a href="#">NCT06283459</a>	Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2	Biological: IMNN-101	Imunon	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06283459</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 미국 58건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06138639</a>	A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)	Genetic: SGT-003	Solid Biosciences Inc.	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06138639">https://clinicaltrials.gov/ct2/show/study/NCT06138639</a>
<a href="#">NCT06340711</a>	Study of Suratadenoturev (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma	Drug: OBP-301 Drug: Pembrolizumab	Weill Medical College of Cornell University Merck Sharp & Dohme LLC Oncolys BioPharma Inc	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06340711">https://clinicaltrials.gov/ct2/show/study/NCT06340711</a>
<a href="#">NCT06333652</a>	Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders	Drug: Ravulizumab	Mayo Clinic	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06333652">https://clinicaltrials.gov/ct2/show/study/NCT06333652</a>
<a href="#">NCT06298019</a>	Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis	Biological: KYV-101	Stanford University	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06298019">https://clinicaltrials.gov/ct2/show/study/NCT06298019</a>
<a href="#">NCT06295770</a>	Obinutuzumab in Treatment of Fibrillary Glomerulonephritis	Drug: Obinutuzumab	Mayo Clinic	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06295770">https://clinicaltrials.gov/ct2/show/study/NCT06295770</a>
<a href="#">NCT06294236</a>	Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)	Biological: SC291	Sana Biotechnology	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06294236">https://clinicaltrials.gov/ct2/show/study/NCT06294236</a>
<a href="#">NCT06263153</a>	Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy	Procedure: Biospecimen Collection Procedure: Computed Tomography Biological: Durvalumab Drug: Futibatinib Procedure: Magnetic Resonance Imaging Procedure: Radical Cystectomy	Yuanquan Yang Gateway for Cancer Research Ohio State University Comprehensive Cancer Center	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06263153">https://clinicaltrials.gov/ct2/show/study/NCT06263153</a>
<a href="#">NCT06254326</a>	ADAGiO: Adoptive Cellular Therapy for the Treatment of Recurrent Oligodendroglioma (OG) Adult Patients	Biological: TTRNA-DC vaccines with GM-CSF Biological: Autologous Hematopoietic Stem cells (HSCs) Biological: TTRNA-xALT Drug: Td vaccine	University of Florida Oligo Nation, Inc	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06254326">https://clinicaltrials.gov/ct2/show/study/NCT06254326</a>
<a href="#">NCT06245889</a>	PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC	Drug: Paclitaxel Drug: Carboplatin Drug: Pembrolizumab Drug: Doxorubicin Drug: Cyclophosphamide Drug: Olaparib Drug: Capecitabine	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06245889">https://clinicaltrials.gov/ct2/show/study/NCT06245889</a>
<a href="#">NCT06124118</a>	Tumor Treating Fields for Locally Advanced NSCLC	Radiation: carboplatin chemotherapy Device: NovoTTF-200T (TTFields) System Drug: Durvalumab	University of Utah	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06124118">https://clinicaltrials.gov/ct2/show/study/NCT06124118</a>
<a href="#">NCT06084780</a>	Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)	Procedure: Intestinal, Multivisceral or Modified Multivisceral Transplantation Drug: Alemtuzumab Drug: Tacrolimus Drug: Sirolimus	Case Comprehensive Cancer Center	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06084780">https://clinicaltrials.gov/ct2/show/study/NCT06084780</a>
<a href="#">NCT05989828</a>	A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer	Biological: Aldesleukin Biological: Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes Procedure: Biopsy Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Cyclophosphamide Procedure: Echocardiography Drug: Fludarabine Procedure: Leukapheresis Procedure: Magnetic Resonance Imaging Procedure: Mammogram Procedure: Multigated Acquisition Scan Procedure: Ultrasound Imaging	University of Southern California National Cancer Institute (NCI)	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05989828">https://clinicaltrials.gov/ct2/show/study/NCT05989828</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 미국 58건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05854966</a>	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Drug: CPI 613 Drug: Metformin Biological: Blood draws Procedure: Bone marrow biopsy	Wake Forest University Health Sciences National Cancer Institute (NCI) Cornerstone Pharmaceuticals	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05854966">https://clinicaltrials.gov/ct2/show/study/NCT05854966</a>
<a href="#">NCT05833867</a>	Adaptive RADIation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer	Drug: Sacituzumab govitecan Radiation: Adaptive Radiotherapy	Omar Mian Varian Inc Gilead Sciences Case Comprehensive Cancer Center	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05833867">https://clinicaltrials.gov/ct2/show/study/NCT05833867</a>
<a href="#">NCT05757310</a>	A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia	Biological: Anti-Thymocyte Globulin Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Drug: Cyclophosphamide Procedure: Haploidentical Hematopoietic Cell Transplantation Drug: Pentostatin Other: Questionnaire Administration	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05757310">https://clinicaltrials.gov/ct2/show/study/NCT05757310</a>
<a href="#">NCT05707702</a>	Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia	Biological: Probiotic oral lozenges Other: Standard of care for oral dysplasia	Boston Medical Center University of Alabama at Birmingham	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05707702">https://clinicaltrials.gov/ct2/show/study/NCT05707702</a>
<a href="#">NCT05664113</a>	Feasibility, Safety, and Potential Efficacy of Fecal Microbiota Transplantation (FMT) for Gastrointestinal Dysfunction in Children Following Hematopoietic Cell Transplant (HCT).	Drug: Fecal microbiota transplant (FMT)	St. Jude Children's Research Hospital	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05664113">https://clinicaltrials.gov/ct2/show/study/NCT05664113</a>
<a href="#">NCT05632328</a>	AGEN1423 Plus Balstilimab With or Without Chemo in Pancreatic Cancer	Drug: AGEN1423 Drug: Balstilimab Drug: Gemcitabine Drug: Nab-paclitaxel	Bruno Bockorny Agenus Inc Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05632328">https://clinicaltrials.gov/ct2/show/study/NCT05632328</a>
<a href="#">NCT05445882</a>	N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate Cancer	Drug: Bintrafusp alfa Drug: N-803 Biological: BN-Brachyury	National Cancer Institute (NCI) National Institutes of Health Clinical Center (CC)	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05445882">https://clinicaltrials.gov/ct2/show/study/NCT05445882</a>
<a href="#">NCT05333029</a>	Extracorporeal Photopheresis and Mesenchymal Stem Cell Infusion for GVHD	Biological: Allogeneic mesenchymal stromal cells (MSCs) Biological: Extracorporeal photopheresis (ECP)	Molly Gallogly Case Comprehensive Cancer Center	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05333029">https://clinicaltrials.gov/ct2/show/study/NCT05333029</a>
<a href="#">NCT05264974</a>	Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy	Biological: Autologous total tumor mRNA loaded DOTAP liposome vaccine	University of Florida	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05264974">https://clinicaltrials.gov/ct2/show/study/NCT05264974</a>
<a href="#">NCT05134740</a>	(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).	Biological: TAA-specific CTLs	Baylor College of Medicine Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05134740">https://clinicaltrials.gov/ct2/show/study/NCT05134740</a>
<a href="#">NCT04579523</a>	<sup>211</sup> At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Cyclophosphamide Drug: Fludarabine Phosphate Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Center National Cancer Institute (NCI)	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04579523">https://clinicaltrials.gov/ct2/show/study/NCT04579523</a>
<a href="#">NCT04569461</a>	Trimodality Approach of Low Dose iONizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)	Drug: pembrolizumab Radiation: Stereotactic body radiation therapy Drug: Short-term androgen deprivation therapy Procedure: Radical Prostatectomy	Daniel George, MD Merck Sharp & Dohme LLC Duke University	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT04569461">https://clinicaltrials.gov/ct2/show/study/NCT04569461</a>
<a href="#">NCT06345027</a>	CHIMERIC ANTIGEN RECEPTOR TREATMENT TARGETING CD70 (SEVENTY)	Biological: Treatment Arm A	Baylor College of Medicine	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06345027">https://clinicaltrials.gov/ct2/show/study/NCT06345027</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 미국 58건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06343402</a>	Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer	Drug: BBO-8520 Drug: Pembrolizumab	TheRas, Inc	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06343402</a>
<a href="#">NCT06336902</a>	Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer	Biological: Balstilimab Procedure: Biospecimen Collection Biological: Botensilimab Procedure: Computed Tomography Other: Dietary Intervention Procedure: Magnetic Resonance Imaging Dietary Supplement: Vitamin C	University of Southern California National Cancer Institute (NCI)	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06336902</a>
<a href="#">NCT06228924</a>	Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC	Genetic: TN-401	Tenaya Therapeutics Johns Hopkins University Mayo Clinic	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06228924</a>
<a href="#">NCT06043674</a>	A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation	Drug: Glofitamab Drug: Obinutuzumab Drug: Polatuzumab Vedotin Drug: Atezolizumab Drug: Tocilizumab	Christine Ryan Genentech, Inc. Dana-Farber Cancer Institute	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06043674</a>
<a href="#">NCT06006013</a>	Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer	Biological: Atezolizumab Procedure: Biospecimen Collection Drug: Cabozantinib S-malate Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging	Emory University National Cancer Institute (NCI)	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06006013</a>
<a href="#">NCT05951777</a>	Autologous Adipose Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury	Biological: Autologous HB-adMSCs Drug: Normal Saline	Hope Biosciences The University of Texas Health Science Center, Houston	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05951777</a>
<a href="#">NCT06345066</a>	A Study of LY3841136 in Overweight and Obese Participants	Drug: Tirzepatide Drug: LY3841136 Drug: Placebo	Eli Lilly and Company	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06345066</a>
<a href="#">NCT06263543</a>	Sequencing Antibody Drug Conjugates in ER+/HER2 LOW MBC	Drug: Sacituzumab govitecan	Reshma L. Mahtani, D.O. Gilead Sciences Baptist Health South Florida	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06263543</a>
<a href="#">NCT06023277</a>	A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer	Biological: ConvitVax	Jacinto Convit World Organization Inc. Fundación Jacinto Convit Istituto Oncologico Luis Razetti	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06023277</a>
<a href="#">NCT06227546</a>	A Phase II Study of MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer	Drug: MGC018	Georgetown University MacroGenics	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06227546</a>
<a href="#">NCT05937152</a>	A Study of CGRP Monoclonal Antibody to Treat Diabetic Neuropathy	Drug: Eptinezumab Drug: Placebo	Mayo Clinic	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05937152</a>
<a href="#">NCT06249048</a>	Study of IT STX-001 in Patients With Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab	Biological: STX-001 Biological: Keytruda	Strand Therapeutics Inc.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06249048</a>
<a href="#">NCT05952804</a>	IVIG for Infection Prevention After CAR-T-Cell Therapy	Biological: Immune Globulin Infusion (Human), 10% Solution Biological: Anti-CD19 CAR T Cells Preparation Other: Saline Procedure: Biospecimen Collection Other: Survey Administration Other: Electronic Health Record Review	Fred Hutchinson Cancer Center Takeda National Cancer Institute (NCI)	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05952804</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

## ○ 미국 58건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT05835206</a>	Further MT for Antibiotic-Resistant Bacterial Colonization in Inpatients	Drug: Microbiome Therapeutic Drug: Placebo	Emory University Centers for Disease Control and Prevention	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05835206</a>
<a href="#">NCT05985681</a>	Testing RG1-VLP Vaccine to Prevent HPV-related Cancers	Procedure: Biospecimen Collection Biological: HPV16 RG1 VLP Vaccine Other: Questionnaire Administration Biological: Recombinant Human Papillomavirus Nonavalent Vaccine Other: Saline	National Cancer Institute (NCI)	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05985681</a>
<a href="#">NCT06071767</a>	Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1	Biological: ChAdOx1.tHIVconsV1 Biological: ChAdOx1.HIVconsV62 Biological: MVA.tHIVconsV3 Biological: MVA.tHIVconsV4 Drug: Vesatolimod (VES) Drug: GS-5423 Drug: GS-2872 Biological: Placebo	National Institute of Allergy and Infectious Diseases (NIAID) University of Oxford Gilead Sciences	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06071767</a>
<a href="#">NCT05703971</a>	Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients	Biological: quaratusugene ozeplasmid Biological: atezolizumab	Genprex, Inc.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05703971</a>
<a href="#">NCT06200207</a>	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06200207</a>
<a href="#">NCT06195072</a>	Platform Clinical Study for Conquering Scleroderma	Drug: Amltelimab Drug: BI 1015550 Drug: Placebo	Scleroderma Research Foundation, Inc. Sanofi Boehringer Ingelheim	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06195072</a>
<a href="#">NCT06131372</a>	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06131372</a>
<a href="#">NCT06014762</a>	P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies	Biological: P-CD19CD20-ALLO1 Drug: Rimiducid	Poseida Therapeutics, Inc. Roche-Genentech	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06014762</a>
<a href="#">NCT05733598</a>	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05733598</a>
<a href="#">NCT06163391</a>	A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer	Drug: SOT201	SOTIO Biotech AG Sotio Biotech Inc.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06163391</a>

## ○ 영국 4건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06320535</a>	A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™	Biological: R21/Matrix M™(Group 1) Biological: R21/Matrix M™(Group 2) Biological: R21/Matrix M™(Group 3) Procedure: Fine needle aspiration (FNA)	University of Oxford Bill and Melinda Gates Foundation University Hospitals Bristol and Weston NHS Foundation Trust	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06320535</a>
<a href="#">NCT05733598</a>	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05733598</a>
<a href="#">NCT06200207</a>	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06200207</a>
<a href="#">NCT05718297</a>	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05718297</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

## ○ 프랑스 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06037460</a>	Tocilizumab discontinuation in Giant Cell Arteritis	Drug: Tocilizumab treatment Other: questionnaires Biological: Blood samples Procedure: 18FDG PET scan	Centre Hospitalier Universitaire Dijon	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06037460">https://clinicaltrials.gov/ct2/show/study/NCT06037460</a>
<a href="#">NCT06276504</a>	Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV Infection	Drug: Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection	Assistance Publique - Hôpital de Paris	Phase 2 Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06276504">https://clinicaltrials.gov/ct2/show/study/NCT06276504</a>
<a href="#">NCT06306014</a>	Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients	Drug: EXL01 Drug: Placebo	Hospices Civils de Lyon Exelium Biosciences	Phase 1 Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06306014">https://clinicaltrials.gov/ct2/show/study/NCT06306014</a>
<a href="#">NCT06284122</a>	Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5	Drug: Mosunetuzumab Drug: Lenalidomide Drug: Rituximab Drug: Obinutuzumab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristin Drug: Prednisone Drug: Bendamustin	The Lymphoma Academic Research Organisation Lymphoma Study Association Swiss Group for Clinical Cancer Research Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06284122">https://clinicaltrials.gov/ct2/show/study/NCT06284122</a>
<a href="#">NCT06131372</a>	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06131372">https://clinicaltrials.gov/ct2/show/study/NCT06131372</a>
<a href="#">NCT05733598</a>	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05733598">https://clinicaltrials.gov/ct2/show/study/NCT05733598</a>
<a href="#">NCT06200207</a>	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06200207">https://clinicaltrials.gov/ct2/show/study/NCT06200207</a>
<a href="#">NCT05718297</a>	Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer	Drug: Brigatinib Drug: Durvalumab	ETOP IBCSG Partners Foundation Takeda	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05718297">https://clinicaltrials.gov/ct2/show/study/NCT05718297</a>
<a href="#">NCT06163391</a>	A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer	Drug: SOT201	SOTIO Biotech AG Sotio Biotech Inc.	Phase 1	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06163391">https://clinicaltrials.gov/ct2/show/study/NCT06163391</a>

## ○ 독일 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06243393</a>	Sacituzumab Govitecan in Metastatic Colorectal Cancer	Drug: Sacituzumab Govitecan (SG) Drug: Physicians Choice (PhC).	University Hospital Heidelberg	Phase 2 Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06243393">https://clinicaltrials.gov/ct2/show/study/NCT06243393</a>
<a href="#">NCT06200207</a>	A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation	Drug: Ziltivekimab Drug: Placebo	Novo Nordisk A/S	Phase 3	<a href="https://clinicaltrials.gov/ct2/show/study/NCT06200207">https://clinicaltrials.gov/ct2/show/study/NCT06200207</a>
<a href="#">NCT05733598</a>	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	<a href="https://clinicaltrials.gov/ct2/show/study/NCT05733598">https://clinicaltrials.gov/ct2/show/study/NCT05733598</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

## ○ 독일 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06163573</a>	Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage.	Biological: N-TEC Biological: Platelet rich plasma	University Hospital, Basel, Switzerland Swiss National Science Foundation Clinical Trial Unit, University Hospital Basel, Switzerland Wuerzburg University Hospital	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06163573</a>
<a href="#">NCT06284122</a>	Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5	Drug: Mosunetuzumab Drug: Lenalidomide Drug: Rituximab Drug: Obinutuzumab Drug: Cyclophosphamide Drug: Doxorubicin Drug: Vincristin Drug: Prednisone Drug: Bendamustin	The Lymphoma Academic Research Organisation Lymphoma Study Association Swiss Group for Clinical Cancer Research Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06284122</a>

## ○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06345482</a>	A Study of MHB039A for Advanced Solid Tumor	Drug: MHB039A	Minghui Pharmaceutical (Hangzhou) Ltd	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06345482</a>
<a href="#">NCT06332950</a>	Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy	Drug: Adebrelimab, Irinotecan Liposome (II) Drug: Adebrelimab, Irinotecan Liposome (II), Famitinib	Baohui Han Shanghai Chest Hospital	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06332950</a>
<a href="#">NCT06283719</a>	Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer	Biological: ZG006	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06283719</a>
<a href="#">NCT05745740</a>	A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation	Drug: RC48-ADC Drug: Pyrotinib	RemeGen Co., Ltd.	Phase 1 Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05745740</a>
<a href="#">NCT06344156</a>	Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer	Drug: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy	Sichuan University	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06344156</a>
<a href="#">NCT06343948</a>	A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer	Drug: BL-B01D1 Drug: Eribulin Drug: Vinorelbine Drug: Gemcitabine Drug: Capecitabine	Sichuan Baili Pharmaceutical Co., Ltd. Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06343948</a>
<a href="#">NCT06341595</a>	Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM	Drug: Sintilimab Radiation: Extraperitoneal radiation therapy Drug: Oxaliplatin Drug: S-1	The First Affiliated Hospital with Nanjing Medical University	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06341595</a>
<a href="#">NCT06331169</a>	Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer	Drug: Anlotinib Drug: Trastuzumab deruxtecan	Fudan University	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06331169</a>
<a href="#">NCT06331026</a>	A Bioequivalence Study of Two Different PEG-rhGH Preparations.	Drug: PEG-rhGH with new preparation (T) Drug: PEG-rhGH with present preparation (R)	Changchun GeneScience Pharmaceutical Co., Ltd.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06331026</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06322563</a>	Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC	Drug: LTC004+regorafenib	Tianjin Medical University Cancer Institute and Hospital	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06322563</a>
<a href="#">NCT06320301</a>	Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)	Drug: Adebrelimab + GEMOX + TKI	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06320301</a>
<a href="#">NCT06316531</a>	A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer	Drug: BL-M07D1 Drug: T-DM1	Sichuan Baili Pharmaceutical Co., Ltd. Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06316531</a>
<a href="#">NCT06313190</a>	Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)	Radiation: Stereotactic body radiotherapy Drug: Sintilimab	Sun Yat-sen University Fifth Affiliated Hospital, Sun Yat-Sen University Ningbo Medical Center Lihuli Eastern Hospital	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06313190</a>
<a href="#">NCT06202716</a>	Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscore	Drug: Cadonilimab plus CapeOX chemotherapy	Nanfang Hospital, Southern Medical University	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06202716</a>
<a href="#">NCT06319456</a>	A Global Study of Lisoftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.	Drug: Lisoftoclax (APG-2575) Drug: Acalabrutinib Drug: Fludarabine Drug: Cyclophosphamide, CTX Drug: Rituximab Drug: Chlorambucil	Ascentage Pharma Group Inc.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06319456</a>
<a href="#">NCT06301386</a>	Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients	Drug: Everolimus Drug: PD-1	Fudan University Anyang Tumor Hospital	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06301386</a>
<a href="#">NCT06206902</a>	F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma	Drug: After preconditioning with chemotherapy, F01 will be evaluated.	Shanghai Simnova Biotechnology Co.,Ltd. Wuhan Union Hospital, China	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06206902</a>
<a href="#">NCT06320080</a>	Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.	Drug: TQB2223 injection Drug: Penpulimab Injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06320080</a>
<a href="#">NCT06318884</a>	A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma	Drug: SCTB35 injection	Sinocelltech Ltd.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06318884</a>
<a href="#">NCT06297642</a>	TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.	Drug: TQB2928 injection Drug: Penpulimab	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06297642</a>
<a href="#">NCT05850546</a>	Rituximab in the First Episode of Paediatric Nephrotic Syndrome	Drug: Rituximab Drug: Corticosteroid	Children's Hospital of Fudan University Shanghai Shen Kang Hospital Development Center Xinhua Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Children's Medical Center Shanghai Children's Hospital	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT05850546</a>

# 해외 바이오의약품 임상 현황 ('24년 4월 1주)

한국바이오의약품협회, 2024.04.09.

## ○ 중국 23건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06205862</a>	Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)	Procedure: fecal microbiota transplantation	Shenzhen Hospital of Southern Medical University	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06205862</a>
<a href="#">NCT06297655</a>	A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A	Drug: Recombinant human activated coagulation factor VIII for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06297655</a>

## ○ 일본 2건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
<a href="#">NCT06297616</a>	A Study of LY3841136 in Japanese Participants With Obesity or Overweight	Drug: LY3841136 Drug: Placebo	Eli Lilly and Company	Phase 1	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06297616</a>
<a href="#">NCT06131372</a>	A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo	Novo Nordisk A/S	Phase 2	<a href="#">https://clinicaltrials.gov/ct2/show/study/NCT06131372</a>